共 36 条
[1]
Ament A., Et al., Cost-effectiveness of pneumococcal vaccination of older people: A study in 5 western European countries, Clin Infect Dis, 31, pp. 444-450, (2000)
[2]
Arikian S., Et al., A multinational pharmacoeconomic analysis of oral therapies for onychomycosis, Br J Dermatol, 130, 43 SUPPL., pp. 35-44, (1994)
[3]
Barbieri M., Et al., Variability of cost-effectiveness estimates for pharmaceuticals in western Europe: Lessons for inferring generalisability, Value Health, 8, pp. 10-23, (2005)
[4]
Berger K., Et al., Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective, Eur J Cancer, 34, pp. 1894-1901, (1998)
[5]
Borghi J., Guest J., Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK, Eur Psychiatry, 1, pp. 378-387, (2000)
[6]
Boulenger S., Nixon J., Rice S., Ulmann P., Drummond M., Guidelines for completing the EURONHEED transferability checklist, EURONHEED Working Paper, (2004)
[7]
Brown M., Et al., Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France, Eur J Psychiatry, 14, pp. 15-25, (2000)
[8]
Chiou C.F., Et al., Development and validation of a grading system for the quality of cost-effectiveness studies, Med Care, 41, pp. 32-44, (2003)
[9]
Reduced costs with bisoprolol treatment for heart failure. An economic analysis of the second Cardiac Insufficency Bisoprolol Study (CIBIS-II), Eur Heart J, 22, pp. 1021-1031, (2001)
[10]
Methodological Guide on the Economic Evaluation of Health Care Interventions, (2003)